SCHEMBL225152

SCHEMBL225152

COc1ccc2c(c1)CCC(c1ccc(OC)cc1CNc1ccc(OCCN3CCCCC3)cc1)=C2

nearest known ligand 0.48

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
EBP Q15125 1/20 0.48
SIGMAR1 Q99720 1/20 0.48
HRH3 Q9Y5N1 5/20 0.46
LTA4H P09960 4/20 0.46
MAOB P27338 1/20 0.43
MCHR1 Q99705 1/20 0.41
ESR1 P03372 2/20 0.41
PSMB1 P20618 1/20 0.40
PSMB5 P28074 1/20 0.40
PSMB2 P49721 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL228208 0.89 EBP (0.47) EBPSIGMAR1HRH3LTA4HMAOB
SCHEMBL227652 0.85 EBP (0.49) EBPSIGMAR1HRH3LTA4HMAOB
SCHEMBL226095 0.84 EBP (0.48) EBPSIGMAR1HRH3LTA4HMAOB
SCHEMBL225413 0.81 LTA4H (0.55) EBPSIGMAR1HRH3LTA4HMAOB
SCHEMBL229521 0.80 LTA4H (0.46) EBPSIGMAR1HRH3LTA4HMAOB
SCHEMBL227767 0.79 LTA4H (0.51) EBPSIGMAR1HRH3LTA4HMAOB
SCHEMBL225153 0.79 EBP (0.49) EBPSIGMAR1HRH3LTA4HMAOB
SCHEMBL228209 0.78 EBP (0.47) EBPSIGMAR1HRH3LTA4HMAOB
SCHEMBL227135 0.77 PSMB1 (0.53) EBPSIGMAR1HRH3LTA4HESR1
SCHEMBL227179 0.77 LTA4H (0.48) EBPSIGMAR1HRH3LTA4HMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1577288-B1 Selective estrogen receptor modulators EISAI R&D MAN CO LTD (JP) 2014-07-23 EP disclosed
US-8399520-B2 Selective estrogen receptor modulator EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-03-19 US disclosed
US-20120004315-A1 Selective Estrogen Receptor Modulator RADIUS HEALTH, INC. 2012-01-05 US disclosed
US-7960412-B2 Selective estrogen receptor modulator EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-06-14 US disclosed
US-20090325930-A1 SELECTIVE ESTROGEN RECEPTOR MODULATOR RADIUS HEALTH, INC. 2009-12-31 US disclosed
US-7612114-B2 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-11-03 US disclosed
US-20060116364-A1 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer EISAI CO., LTD. (JP) 2006-06-01 US disclosed
EP-1577288-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS Eisai Co., Ltd. (JP) 2005-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325930-A1 SELECTIVE ESTROGEN RECEPTOR MODULATOR ESR1, GPER1, ESR2 EBP 123/4885SIGMAR1 778/4885HRH3 561/4885
US-20060116364-A1 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer BRCA1, BCR, RCC1 EBP 51/4885SIGMAR1 2885/4885HRH3 114/4885
US-20120004315-A1 Selective Estrogen Receptor Modulator ESR1, GPER1, ESR2 EBP 107/4885SIGMAR1 743/4885HRH3 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.